Advertisement
A vs BRKR
Which Stock Would AI Choose? Agilent Technologies (A) vs. Bruker (BRKR) Stock Comparison
Key Takeaways
- Agilent Technologies (A) has delivered stronger recent momentum, with an 11.9% gain over the past month and 17.55% year-to-date return, outpacing the S&P 500.
- Bruker (BRKR) reported Q2 2026 revenue of $838.5 million (up 5.2% year-over-year) but faced a GAAP operating loss due to a non-cash goodwill impairment, leading to more volatile price action.
- Both companies operate in the life sciences and analytical instruments sector, with Agilent offering broader scale and consistent earnings beats while Bruker focuses on specialized scientific instrumentation.
- Agilent's upcoming Q3 earnings on August 26 provide a near-term catalyst, supported by raised full-year guidance from prior quarters.
- Market positioning shows Agilent with a larger market capitalization and dividend yield compared to Bruker's lower share price and higher volatility (beta 1.28 vs. 1.25).
- Relative performance favors Agilent in recent market activity, though both stocks trade within established 52-week ranges amid sector-specific demand for lab and research tools.
Introduction
Agilent Technologies (A) and Bruker (BRKR) are established players in the analytical and life sciences instrumentation space, making them relevant for investors seeking exposure to laboratory equipment, diagnostics, and scientific research markets. This comparison examines their business models, recent stock behavior, and relative positioning in the current environment. Traders and long-term investors monitoring sector rotation, earnings momentum, and volatility differences may find the analysis useful for portfolio allocation decisions. The focus remains on verifiable performance metrics and observable market factors without forward projections.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) provides instruments, software, services, and consumables for laboratories in life sciences, applied markets, and diagnostics. In recent market activity, the stock has shown resilience, closing at $159.00 on August 21, 2026, with a 1.73% daily gain and an 11.9% advance over the past month. Year-to-date returns reached 17.55%, exceeding the S&P 500's 12.11%. The company delivered a Q2 2026 earnings beat with EPS of $1.49 (versus $1.41 expected) and revenue of $1.83 billion. Positive sentiment has been supported by operational execution and raised full-year guidance from earlier periods. The shares trade within a 52-week range of $108.35 to $160.47, reflecting steady demand for its analytical solutions amid broader market conditions.
Bruker (BRKR) Overview and Recent Performance
Bruker (BRKR) specializes in high-performance scientific instruments for life sciences, materials research, and industrial applications, including magnetic resonance and mass spectrometry technologies. In recent market activity, shares traded around $59.56 as of late August 2026, within a 52-week range of $28.53 to $65.30. Q2 2026 results showed revenue of $838.5 million, a 5.2% year-over-year increase, though slightly below some expectations; non-GAAP operating income improved while GAAP results reflected a goodwill impairment charge. Bookings grew organically, supporting underlying demand. The stock has exhibited more pronounced swings compared to broader indices, influenced by sector dynamics and company-specific factors. Market capitalization stands near $9 billion, with emphasis on specialized instrumentation growth areas.
Trending AI Robots
Tickeron’s Trending AI Robots page curates top-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating strong alignment with prevailing market conditions earn placement in this section, based on backtested and live performance metrics. Bots feature varied trading styles, strategies, timeframes, and statistics, with many showing annualized returns in double-digit ranges and win rates above 60% in select periods depending on configuration. Users can explore detailed risk-reward profiles and ticker-specific applications. Review the Trending AI Robots page for current options suited to individual objectives.
Head-to-Head Comparison
Agilent Technologies (A) operates at greater scale with diversified exposure across life sciences and applied markets, delivering higher net margins near 19.55% and stronger recent price consistency. Bruker (BRKR) maintains a more specialized focus on niche instrumentation, offering potential for targeted growth but carrying elevated volatility and a recent GAAP loss tied to impairment. Sector exposure overlaps in research tools, yet Agilent benefits from broader end-market momentum while Bruker highlights organic bookings expansion. Risk factors include macroeconomic sensitivity for both, with Agilent showing steadier earnings surprises and Bruker facing occasional one-time charges. Market sentiment has tilted toward Agilent amid its outperformance relative to the S&P 500, creating trade-offs between scale and specialization for investors evaluating positioning.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and relative market positioning in recent weeks, Tickeron’s AI would currently assign a higher probabilistic preference to Agilent Technologies (A) over Bruker (BRKR). Agilent’s stronger year-to-date and monthly gains, combined with consistent beats and upcoming catalysts, suggest more stable momentum within the sector. Bruker’s results reflect solid underlying demand offset by volatility and impairment impacts. This assessment draws from historical patterns and current data without constituting investment guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and BRKR is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileBRKR’s FA Score has 1 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- BRKR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while BRKR’s TA Score has 3 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 4 bearish.
- BRKR’s TA Score: 3 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а -3.13% price change this week, while BRKR (@Medical/Nursing Services) price change was -1.44% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.08%. For the same industry, the average monthly price growth was +11.48%, and the average quarterly price growth was +31.94%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.40%. For the same industry, the average monthly price growth was +0.45%, and the average quarterly price growth was -3.69%.
Reported Earning Dates
A is expected to report earnings on Nov 30, 2026.
BRKR is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical Specialties (+1.08% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-4.40% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| A | BRKR | A / BRKR | |
| Capitalization | 42.3B | 8.54B | 495% |
| EBITDA | 1.96B | 306M | 641% |
| Gain YTD | 10.848 | 19.217 | 56% |
| P/E Ratio | 29.57 | 74.88 | 39% |
| Revenue | 7.23B | 3.46B | 209% |
| Total Cash | 1.81B | N/A | - |
| Total Debt | 3.36B | 1.67B | 201% |
A | BRKR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 46 Fair valued | |
PROFIT vs RISK RATING 1..100 | 98 | 100 | |
SMR RATING 1..100 | 44 | 90 | |
PRICE GROWTH RATING 1..100 | 17 | 42 | |
P/E GROWTH RATING 1..100 | 42 | 4 | |
SEASONALITY SCORE 1..100 | 13 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (10) in the Biotechnology industry is somewhat better than the same rating for BRKR (46) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than BRKR’s over the last 12 months.
A's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as BRKR (100) in the Medical Specialties industry. This means that A’s stock grew similarly to BRKR’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for BRKR (90) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than BRKR’s over the last 12 months.
A's Price Growth Rating (17) in the Biotechnology industry is in the same range as BRKR (42) in the Medical Specialties industry. This means that A’s stock grew similarly to BRKR’s over the last 12 months.
BRKR's P/E Growth Rating (4) in the Medical Specialties industry is somewhat better than the same rating for A (42) in the Biotechnology industry. This means that BRKR’s stock grew somewhat faster than A’s over the last 12 months.
| A | BRKR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 62% | N/A |
| Stochastic ODDS (%) | 2 days ago 58% | 2 days ago 75% |
| Momentum ODDS (%) | N/A | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 73% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 76% |
| Advances ODDS (%) | 7 days ago 60% | 7 days ago 68% |
| Declines ODDS (%) | 2 days ago 63% | 9 days ago 74% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 72% |
| Aroon ODDS (%) | 2 days ago 64% | N/A |
Advertisement